Missing man, 75, last seen in Arnprior driving red 1936 Ford Tudor

Author of the article:

Megan Gillis

Publishing date:

Sep 27, 2021  •  3 days ago  •   •  5 Comments

OTTAWA - Sept. 27, 2021 - Ontario Provincial Police are seeking assistance in locating missing male, 75 y/o Ronald LEBLANC
OTTAWA – Sept. 27, 2021 – Ontario Provincial Police are seeking assistance in locating missing male, 75 y/o Ronald LEBLANC Photo by Handout /OPP via Twitter

Article content

The Upper Ottawa Valley detachment of the Ontario Provincial Police is asking the public to help them find a 75-year-old man who was last seen at the Antrim Truck Stop in Arnprior at about 5 p.m. Sunday.

Ronald LeBlanc was driving a red 1936 model Ford Tudor with Ontario plate 5H1581.

He was described as 5’6″ with a thin build, hazel eyes, balding white hair and a white moustache. He was wearing a dark blue button-up shirt, light blue jeans, flip flops and aviator sunglasses.

Anyone with information was asked to call the OPP at 1-888-310-1122.

https://twitter.com/OPP_COMM_ER/status/1442343897645027328

Article content

Ottawa Citizen Headline News logo

Sign up to receive daily headline news from Ottawa Citizen, a division of Postmedia Network Inc.

By clicking on the sign up button you consent to receive the above newsletter from Postmedia Network Inc. You may unsubscribe any time by clicking on the unsubscribe link at the bottom of our emails. Postmedia Network Inc. | 365 Bloor Street East, Toronto, Ontario, M4W 3L4 | 416-383-2300

Note: This article have been indexed to our site. We do not claim ownership or copyright of any of the content above. To see the article at original source Click Here

Related Posts
닳아버린 신발 밑창…학대 피해 아이의 첫 번째 소원은 ‘엄마랑 살지 않기’ thumbnail

닳아버린 신발 밑창…학대 피해 아이의 첫 번째 소원은 ‘엄마랑 살지 않기’

출생과 동시에 입양된 A군, 초등학교 4학년이던 2020년 12월 경찰서 찾아 학대 피해 사실 밝혀 / A군의 양부모는 아동복지법 위반 혐의로 최근 재판 / 공혜정 대한아동학대방지협회 대표, “A군에게는 어른들이 자기를 지켜줄 거라는 믿음이 없었다” 양부모의 학대에 시달리던 A군이 공혜정 대한아동학대방지협회 대표와 만났을 때 신고 있던 신발의 밑창. 대한아동학대방지협회 제공 양부모의 학대에 시달리던 초등학교 4학년 A군이 2020년…
Read More
Cerner previews its new products and plans for HIMSS22 thumbnail

Cerner previews its new products and plans for HIMSS22

While electronic health record giant Cerner has been in the spotlight of late because of its pending acquisition by Oracle, that is not what the health IT company will be highlighting in the exhibit hall of the upcoming HIMSS Global Health Conference & Exhibition in Orlando, March 14-18. Interoperability, organ donation technologies, public health reporting…
Read More
A Person in Maine Has Died From a Rare Tick-Borne Illness thumbnail

A Person in Maine Has Died From a Rare Tick-Borne Illness

As we welcome the return of warmer weather, it’s important to be aware of ticks—and all the potential risks they carry—as you make the most of the great outdoors. On Wednesday, the Maine Center for Disease Control and Prevention (Maine CDC) announced that a resident of Waldo County, Maine, passed away after contracting Powassan virus,…
Read More
Biden-Harris Administration Provides $759 Million to Bring High-Speed Internet Access to Communities Across Rural America thumbnail

Biden-Harris Administration Provides $759 Million to Bring High-Speed Internet Access to Communities Across Rural America

Funding Includes Awards Made Possible by President Biden’s Bipartisan Infrastructure Law WASHINGTON, D.C., Oct. 27, 2022 – U.S. Department of Agriculture (USDA) Secretary Tom Vilsack today announced that the Department is providing $759 million to bring high-speed internet access (PDF, 204 KB) to people living and working across 24 states, Puerto Rico, Guam and Palau.
Read More
Mixed Results for Tiragolumab/Atezolizumab Combo in PD-L1+ Recurrent Cervical Cancer thumbnail

Mixed Results for Tiragolumab/Atezolizumab Combo in PD-L1+ Recurrent Cervical Cancer

Meeting Coverage > IGCS — Overall response beats historical benchmark, but misses significance target by Mike Bassett, Staff Writer, MedPage Today November 6, 2023 SEOUL, South Korea -- Combining the novel anti-TIGIT monoclonal antibody tiragolumab with atezolizumab (Tecentriq) to treat PD-L1-positive recurrent cervical cancer didn't improve overall response rate (ORR) in the phase II SKYSCRAPER-04
Read More
Index Of News
Total
0
Share